None listed
Conditions
Brief summary
In this study, we will assess the efficacy and safety of a dropless regimen in adequately controlling post-operative inflammation after cataract surgery. This study is a prospective, single-centre, non-randomized single-arm interventional study aiming to evaluate the tolerability of phacoemulsification without post-operative anti-inflammatory and antibiotics. This study will be conducted at the Royal Adelaide Hospital.
Interventions
Over a 6-month period, the intervention will involve patients undergoing standard phacoemulsification cataract surgery in the operating suites at the Royal Adelaide Hospital, with a subconjunctival triamcinolone acetonide (KENACORT) injection (40mg/mL) administered at the end of the surgical procedure. An intracameral injection of antibiotics (1mg/mL cefazolin) will also be administered immediately afterwards in all cases for endophthalmitis prophylaxis and those with known cefazolin allergies w
Over a 6-month period, the intervention will involve patients undergoing standard phacoemulsification cataract surgery in the operating suites at the Royal Adelaide Hospital, with a subconjunctival triamcinolone acetonide (KENACORT) injection (40mg/mL) administered at the end of the surgical procedure. An intracameral injection of antibiotics (1mg/mL cefazolin) will also be administered immediately afterwards in all cases for endophthalmitis prophylaxis and those with known cefazolin allergies will be treated with intracameral moxifloxacin or vancomycin. These injections will be administered by an ophthalmologist. Following surgery, all patients will have at least a 3-month post-operative follow-up period. Follow-up will be performed on day 1, day 7, day 30 and day 60. Patients receiving routine topical corticosteroid drops will be included as control arm subjects. Strategies to monitor adherence to the intervention include checking the patient surgical records.
Sponsors
Prof WengOnn Chan
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion criteria for this study includes patients over 18 years’ of age who are scheduled to undergo phacoemulsification cataract surgery in the Ophthalmology outpatient department or inpatient setting at the Royal Adelaide Hospital between a designated to be announced (TBA) 6-month period.
Exclusion criteria
Exclusion criteria for this study includes pregnant patients, patients with prior intraocular surgery, history of steroid-responsive glaucoma, diabetes mellitus and intraoperative complications such as vitreous loss, zonular dialysis and posterior capsular rupture.
Outcome results
None listed